Quantum Cyber N.V.

What they do

Quantum Cyber N.V. (formerly Mainz Biomed N.V.) historically developed and sold in-vitro diagnostic tests for early cancer detection, primarily the ColoAlert colorectal cancer screening product sold in European markets. In 2025, it licensed mRNA biomarkers and an AI algorithm from Liquid Biosciences for a blood-based pancreatic cancer test, and separately developed PancAlert, a stool-based pancreatic screening test. In February 2026, the board wound down the ColoAlert and next-generation colorectal programs, sold the ColoAlert IP in March 2026, and sold the next-gen IP in April 2026. The company now states it is expanding into post-quantum cybersecurity and AI/quantum computing platforms for unmanned vehicle control systems.

Revenue drivers

• ColoAlert colorectal cancer screening — Historically the flagship product, marketed and sold in European markets during fiscal 2025, but the board decided in February 2026 to wind it down and the IP was sold on March 28, 2026, eliminating this revenue stream.
• Pancreatic cancer screening (blood-based test and PancAlert) — The remaining legacy diagnostics program, consisting of an exclusive license to Liquid Biosciences mRNA biomarkers and AI algorithm for a blood test, plus PancAlert, a stool-based test that has received non-refundable government grant income to cover a percentage of project costs; no revenue is reported from these candidates.
• Post-quantum cybersecurity and AI/quantum computing platforms — The newly announced business focus, integrating AI and quantum computing for control systems for drones, self-driving cars and robotic fleets; no revenue has been reported from this initiative.

Recent performance

Total revenue declined to $537,080 in fiscal 2025 from $893,991 in 2024, reflecting the shrinking legacy diagnostics business. Net loss improved to $16.2 million in 2025 from $21.6 million in 2024, and diluted EPS improved to -$2.70 from -$21.91, with the prior-year per-share figure reflecting a 1-for-40 reverse stock split implemented December 3, 2024. Operating cash flow was negative $11.0 million in 2025, an improvement from negative $17.3 million in 2024. As of June 30, 2026, total assets were $23.4 million, total liabilities $3.0 million, shareholders' equity $20.4 million, and cash and equivalents $13.4 million. The most recent quarterly revenue shown in the XBRL data is $1.00 for the quarter ended March 31, 2023, which is not reflective of current operations.

Strategy

The company is executing a strategic pivot away from colorectal cancer diagnostics toward AI and quantum computing platforms for autonomous vehicle control, including unmanned aerial and underwater vehicles, targeting defense, commercial logistics, disaster response, and critical infrastructure. It completed the divestiture of the ColoAlert IP for $348,966 in March 2026, which reduced debt owed to UTR of $648,966 and resulted in a net payment to UTR of $300,000, and sold the next-generation colorectal IP for $1.25 million in April 2026. The company changed its name from Mainz Biomed N.V. to Quantum Cyber N.V. and its Nasdaq ticker to QUCY in April 2026, and appointed Robert Liscouski as non-executive Chairman with David Lazar as director and CEO. It continues to pursue commercialization of its blood-based pancreatic cancer detection product candidate, and has received non-refundable government grant income for the PancAlert project. Management states it anticipates investing in research and development to power commercialization of its drone technology.

Risks

• Unproven new business line — The AI/quantum computing platform for autonomous vehicles has generated no reported revenue and the company is shifting into a field in which it has no disclosed operating history.
• Revenue decline from wound-down diagnostics — ColoAlert, the historical flagship product, was wound down and its IP sold in March 2026, and revenue had already fallen to $537,080 in 2025 from $893,991 in 2024.
• Cash burn and going-concern pressure — Operating cash flow was negative $11.0 million in 2025, and while cash and equivalents stood at $13.4 million as of June 30, 2026, the company has no reported revenue from its new business to offset ongoing losses.
• Dependence on licensed pancreatic cancer technology — The blood-based pancreatic cancer test relies on an exclusive license from Liquid Biosciences for mRNA biomarkers and an AI algorithm, with a unilateral option to acquire them, creating reliance on a third party for a core remaining asset.

Outlook

Management states it intends to expand into AI and quantum computing platforms for autonomous vehicle control systems and to invest in research and development toward eventual commercialization of drone technology. The company also says it will continue pursuing commercialization of its blood-based pancreatic cancer detection product candidate. No specific revenue guidance, timeline, or funding commitments for these initiatives are provided in the excerpts. The company has approximately 10 full-time and 3 part-time employees as of March 30, 2026, following the termination of employees primarily dedicated to the wound-down colorectal programs.